Cigna Reports Q1 Gains, Announces ACA Marketplace Exit

Cigna’s earnings tell a story Wall Street loves but its retreat from the ACA Marketplace could accelerate a system already tipping toward collapse.

Cigna reported its first-quarter 2026 results last Thursday. Like most of the other big health insurance conglomerates that have reported so far, it did a better job of meeting Wall Street’s profit expectations in the first three months of the year than it did in all of 2025.

Total revenues rose 5% to $68.5 billion. Adjusted income from operations came in at $2.1 billion, or $7.79 per share — up 12% from a year ago, though missing analyst estimates by five cents. The company raised its full-year outlook for adjusted income from operations to at least $30.35 per share. David Cordani, in what he called a “somewhat bittersweet” moment as his final quarterly earnings call as CEO, described the results as reflecting “disciplined execution, deliberate portfolio shaping and a continued focus on targeted innovation.”

That jargon didn’t impress investors. Cigna’s stock price fell $3.19 on Thursday but was up 2.76% for the week, closing Friday at $282.90.

None of that is surprising. Cigna is a well-run company by the metrics Wall Street uses to measure well-run companies. What’s worth examining is what the numbers actually reveal about how the first quarter results were achieved and – equally if not more important – what Cigna announced alongside it.

Another big exit

The biggest news from Thursday’s release and call with analysts wasn’t about earnings. Cigna will stop offering plans on the Affordable Care Act marketplaces after the 2026 plan year. The exit will affect 369,000 members across 11 states, with coverage ending January 1, 2027.

Brian Evanko, who will succeed Cordani as CEO on July 1, framed the decision as a strategic choice to exit a market where Cigna is unlikely to achieve scale. “This is small business for us today, and it’s been shrinking in recent years,” he said.

He’s right about the numbers. What he didn’t say is why it’s shrinking — and what Cigna’s exit will do to the people left behind.

Cigna is by no means the first big insurer to announce an exit from the ACA Marketplace. Aetna pulled out at the end of 2025, forcing approximately 1 million members across 17 states to find new coverage for 2026. But even that headline understates the breadth of the retreat. At the end of 2025, when Congress chose not to renew some of the tax credits that had made ACA coverage affordable for millions of Americans, a wave of smaller insurers also left: Molina Healthcare announced significant changes to its service area; HAP CareSource exited Michigan; Chorus Community Health Plan withdrew; Mountain Health CO-OP left Wyoming; Primewell Health Services exited Arkansas and Mississippi; UM Health Plan and Michigan Care ended; and Celtic/WellCare left North Carolina. Blue Cross Blue Shield terminated PPO products in Arizona. And last month, Baylor Scott & White Health Plan announced it will no longer offer marketplace plans after the end of this year, affecting approximately 100,000 enrollees in Texas.

That means that before open enrollment for 2027 coverage even begins this fall, at least half a million people — Cigna’s 369,000 plus Baylor Scott & White’s 100,000, on top of the million who lost Aetna coverage last year — will either have to scramble to find comparable coverage (at a significantly higher price) or go uninsured.

And we may not yet know the full scope. Every spring and summer, health insurers file proposed premium rates with state regulators — filings that reveal what insurers are planning for the coming year. Those rate filings typically land in May and June. The Q2 earnings season follows in July and August. Each of those moments is an opportunity for another insurer to announce what Cigna announced Thursday. The exits we know about may be the beginning, not the end.

This is not a series of isolated corporate decisions. It is the beginning of a potential death spiral, and it is already in motion.

The mechanism is straightforward. ACA sign-ups for 2026 are already down by over 1 million people compared to the same period last year — the first decline since 2020. The main reason was the December 31, 2025 expiration of the enhanced premium tax credits that were enacted during the Biden administration. For subsidized enrollees who stayed in the same plan, average net premiums rose 114%. When premiums spike, the people who leave first are the healthy ones — younger, lower-utilization enrollees who do the math, decide the cost isn’t worth it and gamble that they’ll have another year of good health. The people who stay are the ones who have no choice: the chronically ill, the older, the people who know they will need care. The marketplace is already smaller and sicker, according to consultants and insurance executives, with more consumers choosing cheaper bronze plans that carry higher out-of-pocket costs.

A smaller, sicker pool means higher claims. Higher claims mean higher premiums. Higher premiums drive out even more healthy enrollees, which makes the pool sicker and more expensive still. And that is exactly what Evanko described when he noted that Cigna’s ACA enrollment had already dropped from 446,000 to 369,000 — a 17% decline in a single year.

The insurers aren’t abandoning a failed program. They are ensuring it fails — and then leaving before it does.

I wasn’t surprised to hear that Cigna is leaving the ACA Marketplace because it has never been a big player in the individual health insurance business. Around 90% of Cigna’s health plan enrollment is in its role as a third-party administrator (TPA) for large employers. The company also has sold all of its Medicare Advantage business.

What did surprise me was the company’s other big reveal: It has put its EviCore unit, which provides prior authorization and utilization management services to health plans (not just Cigna’s), up for sale. Evanko told analysts that the industry’s prior authorization standardization push (which I wrote about last Wednesday) could “open new doors for the EviCore business, which could potentially result in a partnership or a combination with complementary industry participants.”

EviCore is the prior authorization machinery — the infrastructure through which doctors’ requests for patient care get approved, delayed, or denied. Cigna is exploring selling it, or spinning it off, at precisely the moment that prior authorization is under the most intense public and regulatory scrutiny it has ever faced.

Think about what that means. Just days after the industry announced a voluntary reform campaign to standardize the prior authorization process, Cigna said it might sell the business unit that does the prior authorizing. That tells me that the company’s executives don’t think EviCore will be able to continue contributing to Cigna’s profits.

What the numbers say — and don’t

One of the most important numbers in any health insurer’s earnings report isn’t revenue. It’s the medical loss ratio — the percentage of premium dollars actually spent on patient care. The lower the MLR, the more the company keeps.

Cigna’s MLR for Q1 2026 was 79.8%, down from 82.2% a year ago. That 240-basis-point decline is the engine behind the strong earnings performance. For every dollar Cigna collected in premiums this quarter, it paid out roughly two cents less in medical claims than it did a year ago.

The company attributes the decline primarily to the 2025 sale of its Medicare Advantage business to Health Care Services Corporation — older, costlier populations leaving the risk pool.

What no analyst asked: Is the MLR decline connected to Cigna’s prior authorization practices? The company’s own Transparency Report, published in March, claims a 15% reduction in prior authorization volume. Did tighter scrutiny on the remaining high-cost requests contribute to lower medical costs and therefore a better MLR? We don’t know because Wall Street analysts chose not to ask.

Another thing analysts didn’t explore was litigation against its PBM, Express Scripts. Evernorth — the division that encompasses Express Scripts and that now accounts for 85% of Cigna’s revenue — generated $58.4 billion in adjusted revenues, driven by specialty drug volume and biosimilar adoption. What the earnings release doesn’t mention is that Express Scripts is currently the subject of federal RICO litigation alleging the company created a Swiss entity called Ascent Health Services to divert drug rebates away from plan sponsors and patients.

On Thursday’s call, analysts asked about Evernorth’s growth trajectory, capital deployment, the EviCore strategic review, and the CEO transition. No one asked what happens to the 369,000 people who will lose their Cigna coverage on January 1. No one asked whether the cascade of ACA exits constitutes a market failure requiring a policy response. No one asked what the prior authorization denial rate was for the quarter, or how many denials were later overturned on appeal.

Those questions have answers, but Wall Street analysts don’t ask because they assume most investors have little interest in such matters. And they are right.

Health Care Costs is the Issue Voters Can’t Afford to Ignore

New data shows middle-class Americans cutting essentials, dropping coverage, and delaying care — just as Pope Leo XIV calls health care a “moral imperative.”

Pope Leo XIV (who became pope a year ago this week) isn’t just the first American pontiff—he’s also, as a Chicago native and Villanova University alum, the first leader of the Roman Catholic Church to have experienced the U.S. health care system firsthand. So it shouldn’t come as a surprise that this world spiritual leader born as Robert Prevost would use his lofty new platform to call for radical change.

“Health cannot be a luxury for the few,” Leo told a recent conference on health care inequality in Europe organized by both Catholic bishops and the World Health Organization, adding that good health care is essential for social peace.

“Universal health coverage is not merely a technical goal to be achieved; it is primarily a moral imperative for societies that wish to call themselves just,” the pope said. “health care must be accessible to the most vulnerable, then, not only because their dignity requires it but also to prevent injustice from becoming a cause of conflict.”

In less than a year on the job, the new pontiff has shown a lot of political savvy, and a knack for good timing. Leo’s endorsement of health care as a human right coincided with a couple of new, important U.S. surveys showing that both rising insurance premiums and high out-of-pocket medical bills have become the major driver of an affordability crisis that is hitting middle-class families hard.

To back this up, the leading health care non-profit KFF conducted a followup survey with more than 800 Americans who last year had been enrolled in Affordable Care Act (ACA) insurance in 2025. It found broadly that most have been struggling to pay medical bills since Congress failed late last to extend the federal subsidies that had made ACA coverage affordable for many in recent years.

WATCH NOW

HEALTH CARE un-covered

WATCH NOW: Prior Authorization: Care, Delayed | EP 3

In the third episode of the HEALTH CARE un-covered Show, we take a deep dive into prior authorization’s toll — from doctors to federal policy — featuring Dr. Wendy Dean, Dr. Seth Glickman and Rep. Suzan DelBene (D-WA) on CMS’s new AI-driven WISeR model.



Watch the full episode here.

Most of the respondents (80%) said they were paying more now for health care than in 2025, with just over half (51%) reporting they are now spending “a lot more.” For middle-class Americans, the critical need to stay healthy has meant cutting their budget for other essentials. KFF found that a majority (55%) were reducing spending on food or other household basics, but that jumped to 62% for people getting treatment for chronic disease.

Faced with drastically higher monthly premiums, KFF found, has forced these families to make difficult, consequential choices. Some 28% switched into a different ACA plan in an effort to hold down their monthly premiums – which means much higher deductibles and thus the risk of large out-of-pocket medical expenses. Even worse, some 9% told the KFF survey that they have dropped health insurance altogether, which means they are one accident or major illness away from a financial disaster.

A 34-year-old Texan who dropped his Obamacare coverage told the KFF pollsters that the sole reason was the cost. “The prices are simply too high,” he said. “$800 a month for the absolute cheapest plan for two people. Our income is $120k, so we don’t qualify for subsidies in Texas. I don’t think we could afford our mortgage if I had to pay for health insurance.”

Another respondent reported that his “Income exceeded the subsidy limit, forcing us to pay the full cost, so we switched down to a bronze from a gold plan. Even doing that our premiums are 3 times what they were in 2025, with lower plan features and a higher deductible.”

About 22% of the KFF respondents said they are still insured, but not through the ACA Marketplace. In some cases that is because they were able to switch to an employers’ health plan or because they were now eligible for Medicare and Medicaid. But others, KFF noted, switched into different types of high-deductible plans or a cost-sharing group – solutions that often lead to considerable out-of-pocket expenses.

One 56-year-old Texas man surveyed by KFF said that as a reaction to the higher insurance premiums he would “attempt to use health care as little as possible” – with the hope that by carefully consulting with his doctors and pharmacists he would avoid paying any out-of-pocket expenses that aren’t absolutely necessary.

In OMB’s FY 2027 Proposed Budget, Healthcare is the Big Loser

In 1970 before there was ESPN Sports Center, there was ABC’s “Wide World of Sports” and its iconic montage opening featuring a disastrous ski jump attempt by Yugoslavia’s Vinko Bogataj and Jim Kay’s voice-over “the thrill of victory and agony of defeat.” It’s an apt framework for consideration of current affairs in the U.S. today and an appropriate juxtaposition for consideration the winners and losers in the White House Office of Management and Budget FY2027 released Friday.

  • Last week’s “Thrill of Victory” includes the recovery of Dude 14, the F-15E Strike Eagle pilot shot down over Iran Friday, the college basketball men’s and women’s’ Final 4 contests, the successful launch of Artemis II by NASA and, for some, the additional funding ($441 billion/+44% vs. FY 2026) for the Department of War in the President’s proposed budget.
  • And last week’s “Agony of Defeat” includes continued anxiety about the economy, especially fuel prices, growing concern the war in Iran begun February 28 might extend at a heavy cost in lives and money, and for health industry supporters, a $15 billion (-12% vs. FY 2026) cut to HHS and the 10-year, $911 billion Medicaid reduction in federal funding for Medicaid enacted in 2025 (HR1 The Big Beautiful Bill).

In its current form, this budget is unlikely to be enacted October 1, 2026: it’s best viewed as a signal from the White House about priorities it deems most important to the MAGA faithful in Congress, 28 state legislatures and 26 Governors’ offices controlled by Republicans. Though its explosive growth in of War Department funding to $1.5 trillion is eye-popping, cuts to healthcare are equally notable. Both are calculated bets as the mid-term election draws near (6 months) and clearly OMB is betting healthcare cuts will be acceptable to its base. Its view is based on three assumptions:

1- Healthcare cost cutting is necessary to fund other priorities important to its base. And there’s plenty of room for cuts in Medicaid, prescription drugs and hospitals because waste, fraud and abuse are rampant in all.

  • Medicaid: Medicaid is a state-controlled insurance program that covers 76 million U.S. women, children and low-income seniors primarily through private managed care plans that contract with states. In HR1, a mandatory work requirement was applied to able-bodied adult enrollees with the expectation enrollment will drop and state spending for Medicaid services will be less. But its enrollees are less inclined to vote than seniors in Medicare and its funding burden can be shifted to states.
  • Prescription Drugs: The White House asserts its “favored nation” pricing program will bring down drug costs but the combination of voluntary participation by drug companies and impenetrable patent protections in U.S. law neutralize hoped-for cost reductions. The administration wants to lower drug spending using its blunt instruments it already has: accelerated approvals, price transparency, pharmacy benefits manager restrictions et al. while encouraging states to go further through price controls, restrictive formularies and, in some, importation. In tandem, the administration sees CMMI modifications of alternative payment models (i.e. LEAD) as a means of introducing medication management and patient adherence in new chronic care pilots. Recognizing prescription drug prices are a concern to its base and all voters, the administration will use its arsenal of regulatory and political tools to amp-up support for increased state and federal pricing constraints without imposing price controls—a red line for conservatives.
  • Hospitals: Hospital consolidation is associated with higher prices and increased spending with offsetting community benefits debatable. Hospitals represent 43% of total U.S. health spending (31% inpatient and outpatient services, 12% employed physician services). In 4 of 5 U.S. markets, 2 hospital systems control hospital services. And hospital cost increases have kept pace with others in healthcare (+8.9% in 2024 vs. +8.1% for physician services and 7.9% for prescription drugs) but other household costs, wage increases and inflation. Lobbyists for hospitals have historically favored hospital-friendly legislation like the Affordable Care Act preferred by Democrats. The Trump administration sees site neutral payments, 340B reductions, expanded price transparency, limits on NFP system tax exemptions et al. and Medicaid cuts necessary curtailment of wasteful spending by hospitals. They believe voters agree.

Backdrop: Per the National Health Care Fraud Association, 10% of health spending ($560 billion) was spent fraudulently in 2024: the majority in the areas above.

2- The public is dissatisfied by the status quo and supports overhaul of the U.S. healthcare system to increase its affordability and improve its accessibility.

  • Consolidation: Through its Federal Trade Commission and Department of Justice, the White House has served notice it believes healthcare affordability and unreasonable costs are the result of hyper consolidation among hospitals, insurers, and key suppliers in the healthcare supply chain. It has appointed special commissions, task forces, and filed lawsuits to flex its muscle believing the industry has pursued vertical and horizontal consolidation for the purpose of reducing competition and creating monopolies. It shares this view with the majority of voters.
  • Corporatization: In tandem with consolidation, the White House asserts that Big Pharma, Big Insurer, and Big Hospital have taken advantage of the healthcare economy at the expense of local operators and mom and pop services. It presumes they’re run as corporate strongarms that access capital and leverage aggressive M&A muscle to drive out competitors and bolster their margins and executive bonuses. The administration treads lightly on corporate healthcare, seeking financial and political support while voicing populist concerns about Corporate Healthcare. Photo ops with CEOs is valued by the White House; corporatization is recognized as a necessary plus with a few exceptions.  By contrast, most voters see more harm than good. Thus, the administration courts corporate healthcare purposely and carefully.

Backdrop: Intellectually, the majority of voters understand healthcare is a business that requires capital to operate and margins to be sustainable. But many think most healthcare organizations put too much emphasis on short-term profit and inadequate attention on their mission and long-term performance.

3-The U.S. healthcare industry will be an engine for economic growth domestically and globally if regulated less and consumers play a more direct role.

  • The administration is resetting its trade policies in response to suspension of at-will tariff policies that dominated its first year. At home, it seeks improved market access for U.S. producers of healthcare goods and services. It will associate this effort with US GDP growth and expanded privatization in healthcare. And it will assert that expansion of global demand for U.S. healthcare products and services is the result of the administration’s monetary policy geared to innovation and growth. And it will play a more direct role in oversight of foreign-owned/controlled health products and services and impose limits of their use of U.S. data.
  • The administration also seeks to protect intellectual property owned by U.S. inventors and companies by increasing its policing at home and abroad. In this regard, the administration will play a more direct role in the application of AI-enabled solution providers and expedite technology-enabled interoperability.

Backdrop: U.S. healthcare is the world’s most expensive system, so protections against IP theft are important, but the administration’s legacy in healthcare will be technology-enabled platforms that enable scale, democratize science and shift the system’s decision-making (and financial risk) consumer self-care.

Final thought:

The U.S. healthcare system does not enjoy the confidence of the White House: its proposed FY27 budget illustrates its predisposition to say no to healthcare and yes to other pursuits. It bases its position on three assumptions geared to support from its conservative base.

This budget proposal clearly illustrates why state legislators and Governors will play a bigger role in its future at home and abroad. And it means consumer (voter) awareness and understanding on key issues will be key to the system’s future, lest it is remembered for the agony of its defeat than the thrill of its victory.

Why affordability will be a key issue in the 2026 midterm elections

Since the pandemic, Americans have ranked the cost of living (often labeled “affordability”) as the top problem they want America’s leaders to address. The typical household budget has many different components, of course. Some of them, such as health care, have been pressuring families for several decades. Problems in other areas, such as housing, have become acute only in recent years. But the rapid rise in overall prices since the beginning of the pandemic has merged these areas into a broader public concern. Although average hourly wages have risen by 30.8% since then1, costs for many core elements of household budgets have risen even more, and most Americans feel that they are at best running in place.2 Because the rate of price increases remains well above the Federal Reserve Board’s target of 2%, this concern shows no sign of abating, and the effects of the war with Iran will make matters worse.

Health care

Between 1999 and 2024, health care rose from 13% to 18% as a share of GDP, an increase that has serious consequences for family budgets. While wages rose by 119% during this period, workers’ contributions to family health care insurance premiums surged by 308%, almost three times the pace of wages. This increase was not the result of employers shifting the burden of health insurance to workers; the overall cost of insurance premiums rose even faster, by 342%—more than five times as much as the economy-wide rate of inflation. Since the pandemic began, the burden on average families has accelerated: Out-of-pocket expenses per person rose by nearly one-third, from $1,239 to $1,652, in just five years.

Against this backdrop, it is not surprising that health care has risen to the top of Americans’ concerns about affordability.recent survey found that 32% of respondents were “very worried” about health care costs, compared to 24% for food and groceries, 23% for rent or mortgage payments, 22% for utilities, and 17% for gas and other transportation.

Because the problems of health care in the U.S. are structural and deeply rooted, the prospects for quick relief are not bright.

Housing

Unlike health care, the housing affordability crisis mostly began with the pandemic. Since early 2020, the cost of median-priced housing has risen by 28%, from $317,000 to $405,000, while mortgage interest rates surged from 3.45% to 6.11%.

These increases have disrupted the long-established balance between housing prices and household incomes. Until 2020, a median-income household could afford mortgages to buy median-priced homes. Now, households need incomes of $120,000 to qualify for such mortgages, but the median income stands at only $85,000. Otherwise put, families in the middle of the income distribution can afford houses that cost about $330,000, 20% below the sales price of the median home. The result: the majority of homes are now beyond the reach of average families.

This development has hurt young families trying to buy their first homes especially hard. For decades, the median age for first home purchases moved in a narrow range between 29 and 31 years—about when young adults were getting married and starting families. Today, the median age for first home purchases stands at 40 years. Families headed by young adults in their 30s are stuck in apartments that are too small, many in locations that no longer meet their changing needs.

Mounting evidence suggests that the receding prospect for homeownership has troubling ripple effects. Because home ownership is the most reliable source of wealth accumulation for average families, lower rates of homeownership will diminish the assets on which many families can draw as they move through the life cycle. Young adults who have given up on homeownership have no incentive to save for a down payment, reducing their savings rate and encouraging an outlook focused on the present, not the future. Some are plunging into sports betting, while others are turning to risky investments that are hard to distinguish from gambling. When traditional paths to economic mobility seem blocked, the calculus that leads working-class Americans to buy lottery tickets spreads to educated young people. Homeownership has positive externalities that will be hard to replace.

Groceries

For most Americans, trips to the grocery store provide the most regular and vivid indication of what is happening to prices. Since the beginning of the pandemic, the news has been mostly bad. Overall grocery prices have risen by 31% since February 2020, and for some high-profile items—ground beef, for example—the increase has been much steeper.

Even short-term changes are noticeable. The government’s inflation report for February 2026 showed grocery prices rising by 0.4% during the month, an annual pace of roughly 5%. There was bad news for salad-eaters: Lettuce prices rose by 12.2% during the month, and tomatoes, 6.4%. Coffee prices, which rose by 18.4% in 2025, increased by another 1.7% in February.

The surge in energy prices resulting from the war in Iran will probably ratchet grocery prices up another notch. Much of the food U.S. consumers buy is transported long distances from the point of production, and many of the factories that produce fertilizer for U.S. farmers are located in the Persian Gulf.

Other key elements of the affordability issue

Utilities

Household utility costs have risen by 41% in the five years after the beginning of the pandemic. Electricity is up 32%, water 43%, and natural gas 60%, and 17% of households have fallen behind on their monthly electricity bills. These figures help explain the political sensitivity of AI data centers, which consume large amounts of water and put upward pressure on household electricity rates.

Automobiles

Since the onset of the pandemic, the average price of a new car has risen from $38,000 to $50,000, an increase of 32%. Hard-pressed consumers who turned to used cars found little respite; used cars rose by 28% during this period. And auto purchasers have been hit by an array of rising fees, such as “destination charges” for moving purchased autos to the point of sale. Meanwhile, auto insurance premiums have risen by a stunning 55% since the pandemic began.

Child care

Between 2020 and 2024, the average cost of child care rose by 29%, 7 points more than the overall inflation of 22% during these years. Starting in mid-2024, the pace of child care inflation accelerated to twice the rate of overall inflation, a trend that persisted through 2025. Parents are increasingly likely to cite the costs of child-rearing as hard to manage and as a reason to have fewer children than they otherwise would have.

The politics of affordability

The political power of affordability became undeniable when Zohran Mamdani won an improbable victory last November in the contest for mayor of New York, while Mikie Sherrill and Abigail Spanberger won the governorships of New Jersey and Virginia by surprisingly wide margins. Since then, Democratic candidates have continued to press their Republican opponents on the issue, and the inflationary effects of the war in Iran may make the midterms even tougher for the GOP.

The affordability issue has affected President Trump’s standing as well. Most Americans believe that his priorities do not align with theirs, and they want him to focus more on the bread-and-butter challenges they face every day. Whatever the merits of the president’s claim that he inherited these challenges, Americans reject it by a margin of 2-to-1. It is Mr. Trump’s economy now, and Americans want him to do more to fix it than he has so far.

The electorate’s judgment matters because President Trump’s job approval affects his party’s prospects in the forthcoming midterm election. Right now, his dismal approval rating of 34% for his handling of inflation is endangering the survival of Republican House candidates in swing districts and is raising the odds (which are still low) that Democrats will take control of the Senate. With the war in Iran raising energy prices, which will flow through much of the economy, the time for the administration to turn this around is growing shorter.

How China Tripled Health Coverage in Less Than a Decade

Since 2000, most countries around the world have achieved or committed to pursuing universal coverage, or to ensuring their populations have “access to the full range of quality health services” without financial hardship. Nations have, however, pursued different paths to that end. China, with the world’s largest health system, achieved near-universal coverage in just over a decade. In 2000, less than a third of its citizens and permanent residents had coverage; by 2011, that figure had risen to 95 percent. While China’s highly centralized political system differs from many other countries, the government’s focus on rural and unemployed residents and its targeted health infrastructure investments can offer insights for policymakers around the world. China’s Pathway to Universal Coverage By the late 1990s, China’s collective and work-unit-based health insurance systems had largely collapsed following market reforms in the 1980s and 1990s. In 1998, the government launched Urban Employee Basic Medical Insurance (UEBMI), a mandatory program for employed people financed by a payroll tax. In response to the poor performance of the Chinese health system during the 2002 SARS outbreak, the Chinese government moved to make major improvements. This was realized in 2003 and 2007, when the New Rural Cooperative Medical Scheme and Urban Residents Basic Medical Insurance were introduced to cover rural residents and urban unemployed citizens, respectively. To reduce inequities between the two groups, both programs were merged in 2016 to create Urban and Rural Resident Basic Medical Insurance (URRBMI). Today, UEBMI and URRBMI make up China’s basic medical insurance, which partially covers in- and outpatient care, primary and mental health care, pharmaceuticals, traditional Chinese medicine, and dental and eye care. Coverage grew rapidly between 2008 and 2011 through significant government subsidies for those enrolled in the two programs that now make up URRBMI, as well as massive government investment in improving primary care and public hospitals, and establishing a national essential drug list.
Intl_Insights_exhibit_April-2026_China-coverage-expansion_vol48_800
Since these coverage gains, China has seen a significant improvement in overall health outcomes, including a seven-year increase in average life expectancy, a 73 percent decrease in maternal mortality, an 86 percent decrease in child mortality, and lower rates of communicable diseases. However, China’s basic medical insurance faces some key challenges. Given China’s lower per capita income and more limited fiscal capacity compared to the United States, the government prioritizes universal baseline coverage rather than comprehensive benefits, resulting in high out-of-pocket costs — roughly a third of total health expenditures. The basic medical insurance program also has struggled to address systemic inequities between rural and urban residents. For example, the urban employed populations covered by UEBMI receive more comprehensive benefits packages, including medical savings accounts for out-of-pocket expenses. Migrant workers — who make up a fifth of China’s population — are another demographic whose coverage can be fragmented, partly because of the difficulty transferring between different insurance programs if they move to and from rural and urban areas. China also faces major challenges in health care delivery. Lacking a strong primary care system or primary care gatekeeping, hospitals are vastly overused by patients. When you add growing care utilization by China’s rapidly aging population and some people dropping coverage due to rising premiums and copayments, you get a health system under increasing pressure. In 2025, to ease some of this strain, the government announced plans to incentivize long-term enrollment by increasing government subsidies for length of time enrolled and developing long-term care insurance programs focused on older people. America’s Patchwork Health Insurance System Prior to 2010, the United States relied on a fragmented, employment-based health insurance system made up of private, largely employer-sponsored insurance and public programs like Medicaid and Medicare. It left nearly 16 percent of the population, more than 40 million Americans, uninsured. More people gained coverage following full implementation of the Affordable Care Act (ACA) in 2014, which:Expanded Medicaid eligibilityPrevented coverage denials for people with preexisting conditionsAllowed young adults to stay on their parents’ insurance until age 26Established health insurance marketplaces to purchase private plans.By 2023, the U.S. uninsured rate declined to an all-time low of 7.9 percent. However, following passage of the Trump administration’s budget reconciliation bill in July 2025 — featuring $900 billion in Medicaid cuts over the next 10 years — the U.S. is expected to return to pre-ACA highs of nearly 40 million uninsured by 2034.
Intl_Insights_fact_800_vol48
U.S. coverage expansion relies heavily on voluntary enrollment in private plans, often with high deductibles and cost sharing, creating sizeable affordability barriers. In 2024, out-of-pocket costs increased to $1,632 per capita. For subsidized care through Medicaid or cost-sharing reductions, qualification is dependent on income and area of residence, creating variable coverage from state to state. While China structured its reforms to explicitly incorporate rural residents, unemployed urban residents, and migrant workers, U.S. coverage is hampered by the exclusion of groups like undocumented migrants and people with low incomes in non-Medicaid-expansion states. China and the United States have taken remarkably different paths to expanding health insurance coverage. The U.S. has relied on a fragmented public–private model with variable and dwindling government subsidies, resulting in persistent disparities in coverage and access — both of which are expected to only worsen in the coming decade. Meanwhile, despite a vastly different political structure to the U.S., China’s coverage gains are notable due to its massive population (nearly four times the U.S. population) and much lower per capita income. China offers a unique case study of a coordinated health insurance system designed to address disparities in access, ultimately achieving near-universal coverage in just over 10 years.

What Is Medicaid’s Value?

What is Medicaid?

Medicaid is the public health insurance program for people with low income, including children, some adults, pregnant women, and people with disabilities. It was created in 1965 along with Medicare, the federal program that covers adults over age 65 and some people with disabilities, to expand access to a range of health services and to improve health outcomes for these groups.

More than 72 million people are enrolled in Medicaid, making it the single largest insurer in the United States. It is the principal source of health insurance for Americans with low incomes and covers a wide range of services, from preventive care to hospital stays and prescription drugs. Medicaid also pays for nearly half of all U.S. births, as well as end-of-life care for millions of Americans.

While the federal government and the states jointly fund Medicaid, each state runs its own program, subject to federal requirements. The federal government covers between 50 percent and 77 percent of the cost of insuring people with Medicaid, depending on the state.

What is Medicaid expansion?

The Affordable Care Act (ACA) expanded the number of Americans who are eligible for Medicaid and increased the federal government’s contribution toward covering these new enrollees. Starting in 2014, states became eligible for this additional federal funding if they expanded Medicaid eligibility for all adults up to 138 percent of the federal poverty level ($28,207 for a family of two, as of 2024). The ACA also made it easier for people to enroll in Medicaid, such as by eliminating the need for in-person interviews, reducing the amount of information applicants need to provide, and using data from other federal and state agencies to electronically verify eligibility information.

So far, 40 states, along with Washington, D.C., have expanded Medicaid as allowed under the ACA. The federal government pays for 90 percent of the coverage costs for new enrollees under the expansion; states pay for the remaining 10 percent.

What is Medicaid’s impact on health care access and health outcomes?

There is ample evidence showing that Medicaid coverage helps people gain better access to health care services, leading to improvements in health and well-being. Researchers found that low-income adults in Arkansas, which expanded Medicaid eligibility in 2014, have better access to primary care and preventive health services, improved medication compliance, and better self-reported health status than their counterparts in Texas, which has not expanded eligibility for the program. (It should be noted, however, that some of Arkansas’s gains were eroded in 2018, when the state became the first to implement work requirements for Medicaid beneficiaries.)

Other studies show Medicaid expansion is associated with decreased mortality rates, increased rates of early cancer diagnosis and insurance coverage among cancer patients, improved access to care for chronic disease, improved maternal and infant health outcomes, and better access to medications and services for people with behavioral and mental health conditions.

How does Medicaid expansion affect uninsured rates?

States that have expanded Medicaid have a much lower uninsured rate than states that haven’t, and the gap continues to widen. The uninsured rate in expansion states dropped 6.4 percentage points between 2013 and 2017, from 13 percent to 6.6 percent, according to census data. Moreover, health care disparities narrowed between whites, Blacks, and Hispanics in expansion states, with smaller differences seen in uninsured rates among working-age adults, as well as in the percentages who skipped needed care because of costs or who lacked a usual care provider.

The coverage gains in states that have expanded their Medicaid program are not solely the result of newly eligible individuals enrolling. Some of the gains are due to the enrollment of individuals already eligible for Medicaid who took the opportunity to sign up for the first time (sometimes referred to as the “welcome mat effect”).

What are the financial impacts of Medicaid expansion?

Medicaid expansion protects beneficiaries from financial stress by improving access to affordable care. national study found that expansion was associated with significant improvements in low-income people’s financial well-being, leading to reduced levels of debt in collections and unpaid bills. People living in expansion states are also less likely than those in nonexpansion states to have medical debt. Another study comparing the experiences of low-income adults in Texas, which has not expanded Medicaid, to those of low-income adults in three southern states that have expanded Medicaid found that Texas respondents were much more likely to report financial barriers to getting health care.

Medicaid expansion has improved the financial stability of community health centers and safety-net hospitals. There is also evidence that Medicaid expansion provides an economic boost to states. Recent studies of expansion’s financial impacts all find positive economic effects for states, such as growth in the health sector and greater tax revenue from increased economic activity. Expanding Medicaid can also save states money by offsetting costs in other areas, including uncompensated care for the uninsured, mental health and substance use disorder treatment, and other non-Medicaid health programs. After accounting for these new savings and revenues, the net cost of expansion for states is much lower than its 10 percent “sticker price.” In some states, expansion has already paid for itself.

In OMB’s FY 2027 Proposed Budget, Healthcare is the Big Loser

In 1970 before there was ESPN Sports Center, there was ABC’s “Wide World of Sports” and its iconic montage opening featuring a disastrous ski jump attempt by Yugoslavia’s Vinko Bogataj and Jim Kay’s voice-over “the thrill of victory and agony of defeat.” It’s an apt framework for consideration of current affairs in the U.S. today and an appropriate juxtaposition for consideration the winners and losers in the White House Office of Management and Budget FY2027 released Friday.

  • Last week’s “Thrill of Victory” includes the recovery of Dude 14, the F-15E Strike Eagle pilot shot down over Iran Friday, the college basketball men’s and women’s’ Final 4 contests, the successful launch of Artemis II by NASA and, for some, the additional funding ($441 billion/+44% vs. FY 2026) for the Department of War in the President’s proposed budget.
  • And last week’s “Agony of Defeat” includes continued anxiety about the economy, especially fuel prices, growing concern the war in Iran begun February 28 might extend at a heavy cost in lives and money, and for health industry supporters, a $15 billion (-12% vs. FY 2026) cut to HHS and the 10-year, $911 billion Medicaid reduction in federal funding for Medicaid enacted in 2025 (HR1 The Big Beautiful Bill).

In its current form, this budget is unlikely to be enacted October 1, 2026: it’s best viewed as a signal from the White House about priorities it deems most important to the MAGA faithful in Congress, 28 state legislatures and 26 Governors’ offices controlled by Republicans. Though its explosive growth in of War Department funding to $1.5 trillion is eye-popping, cuts to healthcare are equally notable. Both are calculated bets as the mid-term election draws near (6 months) and clearly OMB is betting healthcare cuts will be acceptable to its base. Its view is based on three assumptions:

1- Healthcare cost cutting is necessary to fund other priorities important to its base. And there’s plenty of room for cuts in Medicaid, prescription drugs and hospitals because waste, fraud and abuse are rampant in all.

  • Medicaid: Medicaid is a state-controlled insurance program that covers 76 million U.S. women, children and low-income seniors primarily through private managed care plans that contract with states. In HR1, a mandatory work requirement was applied to able-bodied adult enrollees with the expectation enrollment will drop and state spending for Medicaid services will be less. But its enrollees are less inclined to vote than seniors in Medicare and its funding burden can be shifted to states.
  • Prescription Drugs: The White House asserts its “favored nation” pricing program will bring down drug costs but the combination of voluntary participation by drug companies and impenetrable patent protections in U.S. law neutralize hoped-for cost reductions. The administration wants to lower drug spending using its blunt instruments it already has: accelerated approvals, price transparency, pharmacy benefits manager restrictions et al. while encouraging states to go further through price controls, restrictive formularies and, in some, importation. In tandem, the administration sees CMMI modifications of alternative payment models (i.e. LEAD) as a means of introducing medication management and patient adherence in new chronic care pilots. Recognizing prescription drug prices are a concern to its base and all voters, the administration will use its arsenal of regulatory and political tools to amp-up support for increased state and federal pricing constraints without imposing price controls—a red line for conservatives.
  • Hospitals: Hospital consolidation is associated with higher prices and increased spending with offsetting community benefits debatable. Hospitals represent 43% of total U.S. health spending (31% inpatient and outpatient services, 12% employed physician services). In 4 of 5 U.S. markets, 2 hospital systems control hospital services. And hospital cost increases have kept pace with others in healthcare (+8.9% in 2024 vs. +8.1% for physician services and 7.9% for prescription drugs) but other household costs, wage increases and inflation. Lobbyists for hospitals have historically favored hospital-friendly legislation like the Affordable Care Act preferred by Democrats. The Trump administration sees site neutral payments, 340B reductions, expanded price transparency, limits on NFP system tax exemptions et al. and Medicaid cuts necessary curtailment of wasteful spending by hospitals. They believe voters agree.

Backdrop: Per the National Health Care Fraud Association, 10% of health spending ($560 billion) was spent fraudulently in 2024: the majority in the areas above.

2- The public is dissatisfied by the status quo and supports overhaul of the U.S. healthcare system to increase its affordability and improve its accessibility.

  • Consolidation: Through its Federal Trade Commission and Department of Justice, the White House has served notice it believes healthcare affordability and unreasonable costs are the result of hyper consolidation among hospitals, insurers, and key suppliers in the healthcare supply chain. It has appointed special commissions, task forces, and filed lawsuits to flex its muscle believing the industry has pursued vertical and horizontal consolidation for the purpose of reducing competition and creating monopolies. It shares this view with the majority of voters.
  • Corporatization: In tandem with consolidation, the White House asserts that Big Pharma, Big Insurer, and Big Hospital have taken advantage of the healthcare economy at the expense of local operators and mom and pop services. It presumes they’re run as corporate strongarms that access capital and leverage aggressive M&A muscle to drive out competitors and bolster their margins and executive bonuses. The administration treads lightly on corporate healthcare, seeking financial and political support while voicing populist concerns about Corporate Healthcare. Photo ops with CEOs is valued by the White House; corporatization is recognized as a necessary plus with a few exceptions.  By contrast, most voters see more harm than good. Thus, the administration courts corporate healthcare purposely and carefully.

Backdrop: Intellectually, the majority of voters understand healthcare is a business that requires capital to operate and margins to be sustainable. But many think most healthcare organizations put too much emphasis on short-term profit and inadequate attention on their mission and long-term performance.

3-The U.S. healthcare industry will be an engine for economic growth domestically and globally if regulated less and consumers play a more direct role.

  • The administration is resetting its trade policies in response to suspension of at-will tariff policies that dominated its first year. At home, it seeks improved market access for U.S. producers of healthcare goods and services. It will associate this effort with US GDP growth and expanded privatization in healthcare. And it will assert that expansion of global demand for U.S. healthcare products and services is the result of the administration’s monetary policy geared to innovation and growth. And it will play a more direct role in oversight of foreign-owned/controlled health products and services and impose limits of their use of U.S. data.
  • The administration also seeks to protect intellectual property owned by U.S. inventors and companies by increasing its policing at home and abroad. In this regard, the administration will play a more direct role in the application of AI-enabled solution providers and expedite technology-enabled interoperability.

Backdrop: U.S. healthcare is the world’s most expensive system, so protections against IP theft are important, but the administration’s legacy in healthcare will be technology-enabled platforms that enable scale, democratize science and shift the system’s decision-making (and financial risk) consumer self-care.

Final thought:

The U.S. healthcare system does not enjoy the confidence of the White House: its proposed FY27 budget illustrates its predisposition to say no to healthcare and yes to other pursuits. It bases its position on three assumptions geared to support from its conservative base.

This budget proposal clearly illustrates why state legislators and Governors will play a bigger role in its future at home and abroad. And it means consumer (voter) awareness and understanding on key issues will be key to the system’s future, lest it is remembered for the agony of its defeat than the thrill of its victory.

Hospitals That Sue You for Getting Sick

Hospitals in just one state filed 1.15 million lawsuits — enabled by insurance plans that shift costs to patients while shielding themselves from the fallout.

“People are having to choose between going to the hospital and staying home and dying. Because at least my family won’t be burdened with a lawsuit if I die at home.”

That’s not a line from a dystopian novel. It’s what a real patient — identified only as GV0242002 in court records — told researchers after being sued by Sentara Health, Virginia’s largest hospital system and its most prolific medical debt litigant.

A major new report from researchers at George Washington University Law School and Stanford University’s Clinical Excellence Research Center, produced with PatientRightsAdvocate.org, documents what happens when American health care’s hidden costs finally catch up with the people least able to pay them. The findings for Virginia alone are staggering: between 2010 and 2024, hospitals and medical providers filed 1.15 million lawsuits against patients, seeking to collect $1.4 billion in medical debt. They followed those suits with more than 400,000 garnishment orders targeting wages and bank accounts. Plaintiffs’ attorneys collected $87 million in fees. Courts tacked on another $46 million in costs. And some providers charged interest as high as 18% annually — four times the prevailing commercial rate — buried in consent documents patients signed while frightened, in pain, and in no position to negotiate.

Read the full report here.

Among the top garnishee employers? Walmart, public schools, grocery stores and the hospitals themselves. Nonprofit hospitals in Virginia filed more than 4,100 garnishment orders against their own employees.

As the report notes, the hospitals’ patients have almost no way of knowing how much an inpatient stay or an outpatient service will cost or how much they will be on the hook for even if they are insured. The researchers describe health care providers operating “with insurers as accomplices” in keeping prices hidden from patients. That word — accomplices — is important and appropriate. This is not just a hospital story with an insurance footnote. It is also an insurance story. Both hospitals and insurers are complicit, although I would argue that hospitals have to operate in a system that is increasingly controlled by Big Insurance. That said, the relationship between hospitals and insurers is symbiotic, and the cost-sharing requirements imposed by insurers and the opacity of the agreements they enter into with hospitals enables both parties to increase prices and premiums in a way that ensures a rate of medical inflation that is perennially much higher than regular inflation and wage increases.

Here is the mechanism. An insurer designs a health plan with a $4,000 or $6,000 or $8,000 deductible. A patient — let’s say she works at a Kroger in Charlottesville, covered by her employer’s plan — gets sick and goes to Sentara Martha Jefferson Hospital. She signs an admissions agreement she cannot meaningfully read, consenting to pay “charges” based on a chargemaster that reflects prices no willing purchaser would ever agree to. She receives care. Weeks later, she gets a bill she cannot understand, for an amount she cannot verify, tied to prices that were never disclosed. She can’t pay. The hospital refers the account to one of the 20 law firms that brought more than half of all medical debt cases in Virginia during this period. She gets sued. The insurer that collected her premium — and her employer’s premium contribution — faces no lawsuit, no garnishment, no reputational consequence. It moves on to the next enrollment cycle.

The report covers 2010 through 2024 — the first 14 years of the Affordable Care Act. The ACA expanded coverage and has saved countless lives. But it did not stop the proliferation of high-deductible health plans that left millions of newly insured Americans technically covered and financially exposed. In fact, the ACA legitimized them. Since 2000, employer-sponsored family health insurance premiums have risen 321%, according to data cited in the report, and deductibles and other out-of-pocket costs have also skyrocketed. Wages rose 123% over the same period.

Patients are not drowning in medical debt because they are irresponsible. They are drowning because the insurance industry spent years engineering products that shift financial risk onto health plan enrollees and then collecting ever-increasing premiums for doing so.

I should note one finding with particular resonance for me personally. Ballad Health — the dominant hospital system serving the Tri-Cities of Northeast Tennessee and Southwest Virginia, the region where I grew up — filed 26,300 lawsuits against patients during this period. Ballad was created through a controversial 2018 merger that was granted antitrust immunity under a rare state certificate of public advantage, in exchange for commitments to maintain services and community benefit. The merger eliminated competition across one of the poorest stretches of Appalachia, leaving patients in communities like Scott County, Lee County, and Wise County, Virginia — some of the most economically distressed in either state — with effectively no choice in where they seek care.

Whether Ballad has honored its merger commitments has been disputed ever since. What is no longer in dispute: The system that was handed a regional monopoly turned around and sued its captive patients tens of thousands of times. Wise County, for those who don’t know, is also where Remote Area Medical for years set up a makeshift clinic at the county fairgrounds — the place that first showed me, up close, what this industry does to people when it stops pretending.

Virginia’s legislature took a meaningful step last year to give patients some relief. Former Governor Glenn Youngkin signed the Medical Debt Protection Act last May, capping interest on medical debt at 3%, eliminating interest for the first 90 days, and barring hospitals from foreclosing on homes or placing property liens. Those are real protections, and they matter. But as the researchers note, the law does almost nothing about the hidden prices and opaque billing at the point of care that generate the debt in the first place. The legislature addressed the collection machinery. It did not touch the engine driving it.

That engine — high cost-sharing, hidden prices, insurer-designed benefit structures that make patients financially liable before they walk through the door — is what I’ll be examining in depth in the coming weeks, as the major insurers report their first-quarter 2026 earnings. The Virginia data describe how this system costs patients. The earnings reports will tell you how it benefits big insurers and their shareholders.

Stay with me.


WSJ’s Editorial Board Contradicts What Its Newsroom Has Reported on Medicare Advantage

The Wall Street Journal’s Editorial Board vs. The Wall Street Journal’s Newsroom.

The paper that exposed Medicare Advantage’s $50 billion overbilling scheme is now urging the government to make it the default for every senior in America.

During my two decades working for Big Insurance, I learned what industry spin looks like. I know what it sounds like. And I know that when a major newspaper’s editorial board publishes a piece defending an industry that has spent millions cultivating its editorial goodwill, the result often reads exactly like the Wall Street Journal’s editorial yesterday, “The Truth About Medicare Advantage.”

The piece is a masterclass in selective evidence. But what makes it remarkable is that the most damning rebuttal to it doesn’t come from me, or from Medicare Advantage’s many critics, or from the political left. It comes from the Wall Street Journal’s own newsroom.

In the fall of 2022, a team of Journal reporters did something extraordinary. They negotiated a data-sharing agreement with the Centers for Medicare and Medicaid Services, gaining access to 1.6 billion Medicare Advantage records over a 12-year period — every prescription filled, every doctor visit, every hospitalization. The investigation that followed was among the most rigorous pieces of health care journalism in years.

What they found was damning. Medicare Advantage plans received roughly $50 billion in payments between 2018 and 2021 for diagnoses that were questionable — conditions added to patients’ records not by their doctors, but by the insurers themselves. The Pulitzer Prize committee called it a series showing how health insurers gamed the Medicare Advantage program to collect billions for nonexistent ailments while shunting expensive cases onto the public.

The Journal’s editorial board was apparently not paying attention to its own reporters. Because in its editorial yesterday, the board cites a study funded by Elevance Health — one of the largest Medicare Advantage insurers in the country — to argue that private MA plans reduce Medicare spending. It calls opposition to Medicare Advantage “ideological, no matter the facts.”

“No matter the facts” certainly applies to the Journal’s editorial.

The central fact the editorial board cannot afford to acknowledge — because the entire argument would collapse if it did — is the ongoing Medicare Advantage overpayment scandal. MedPAC, the independent congressional agency that advises Congress on Medicare, projects that for 2026, Medicare Advantage payments will run $76 billion — or 14% — above what traditional Medicare would spend on the same beneficiaries, after accounting for health status, coding differences, and geographic factors. Note that the $76 billion in overpayments is just for this year. Looking back over the history of the Medicare Advantage program and the total likely would grow to nearly a trillion dollars if not more.

This is not a partisan number. MedPAC is a nonpartisan body. The methodology accounts for the very factors the industry argues should be included. And the conclusion is unambiguous: the federal government spends substantially more of our tax dollars per person under Medicare Advantage than it would under traditional Medicare. That $76 billion overpayment is not a rounding error. It is more than the entire annual budget of the Department of Education.

The Journal’s editorial board also ignores what that overpayment costs seniors who never chose a private plan. The Journal’s own reporting detailed how MA overpayments translated into roughly $13.4 billion in additional Part B premium costs in 2025 alone — costs borne by every Medicare beneficiary, including those in traditional Medicare who never signed up for a private Medicare replacement plan, which is what Medicare Advantage is. Every senior paying Part B premiums is, in effect, subsidizing the insurers the editorial board is championing.

The editorial argues that Medicare Advantage reduces the incentives for hospitals to upcode patients to a higher level of complexity. This would be a compelling point if the Journal’s own investigation had not spent years documenting how MA insurers themselves are the upcoding problem.

The Journal’s investigation found that coding intensity in Medicare Advantage runs 20% higher than in traditional fee-for-service Medicare. Of the 17 audits the Department of Health and Human Services Office of Inspector General has conducted since 2019, there was no support for nearly 69% of diagnoses that Medicare Advantage plans used for risk adjustment, leading to more than $100 million in overpayments to MA plans from upcoding alone. That’s not a rounding error either.

In the early years of private Medicare plans, insurers went to great lengths to sign up only the healthiest seniors and to run off the seniors when they got sick. It was called “cherry picking” and “lemon dropping.” I saw it up close in the early ‘90s when I was at Humana, one of the first insurers to get into the private Medicare replacement business. It was so prevalent in the industry that in 2003 Congress passed legislation to authorize the government to pay insurers more for signing up less-healthy seniors. So for two decades now, insurers have been paid more for sicker patients, which means they have powerful financial incentives to make patients look sicker on paper — but not to pay for treatments they supposedly would need. The Journal’s reporters found that among Medicare Advantage beneficiaries who had an HIV diagnosis added to their record by their insurer, just 17% received any treatment for the disease. Among beneficiaries diagnosed with HIV by their own physician, 92% received treatment. Diagnoses without treatment are not better care. They are extra revenue.

The editorial’s most revealing sentence may be this one: “The opposition to Advantage is ideological, no matter the facts.” This is a tell. It reframes data as politics, and politics as bias — a classic spin move designed to preempt legitimate criticism by impugning the critic’s motives.

But the criticism of Medicare Advantage is most certainly not ideological, and it is not coming only from Democrats. Sen. Chuck Grassley of Iowa, a Republican, wrote to UnitedHealth Group’s CEO arguing that the “apparent fraud, waste, and abuse at issue is simply unacceptable and harms not only Medicare beneficiaries, but also the American taxpayer.” The Trump administration’s Department of Justice opened a criminal investigation into UnitedHealth Group’s Medicare Advantage billing practices (which the Journal reported as a scoop). The Senate Judiciary Committee, which Grassley chairs, published a 104-page report on MA overbilling.

Another senior Republican, Sen. Bill Cassidy, who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, is the lead sponsor of a bill that would crack down on upcoding. It’s called The No UPCODE Act. These are not the actions of ideologues. They are the actions of Republican legislative leaders and committee investigators who read the Journal’s own reporting and followed up.

The editorial’s timing is no coincidence. Trump’s Medicare director, Chris Klomp, recently confirmed that the administration is actively considering a policy that would automatically enroll new Medicare beneficiaries into private Medicare Advantage plans — a proposal straight out of the Project 2025 blueprint. The editorial reads, at least in part, as advance justification for that policy.

Under current law, seniors who enroll in Medicare are automatically covered by traditional Medicare unless they affirmatively choose a private plan. Under a default enrollment scheme, the reverse would be true: seniors who fail to make an active choice would be placed into a private plan, with the option to switch back – but not for three years. Seniors would be locked in a plan that the government chose for them, that has a limited network of doctors and hospitals, that makes them pay the entire bill for services they might receive outside of that network, and that denies coverage for medically necessary care far more than traditional Medicare – for three years.

The consequences of getting automatic enrollment in MA wrong are severe and often irreversible. The vast majority of states do not require Medigap insurers to sell supplemental coverage to beneficiaries who want to switch back from Medicare Advantage to traditional Medicare outside of limited time windows. For many seniors, once they are in, they are in. The editorial board does not mention this.

And the program is hardly the stable backstop the board describes. A Johns Hopkins Bloomberg School of Public Health analysis found that approximately 10% of Medicare Advantage enrollees — roughly 2.9 million seniors — are being forced to find new coverage in 2026 as insurers exit markets, a tenfold increase in the forced disenrollment rate compared to just two years ago. The board wants to make this the default destination for every new senior in America, just as the private market is demonstrating it cannot sustain its current commitments.

Let’s return to the study the editorial board cites as evidence that Medicare Advantage saves money. The board presents it as peer-reviewed fact. What it does not say is that the researchers are affiliated with Elevance Health — formerly Anthem — one of the largest Medicare Advantage insurers in the country. Industry-funded research is not automatically wrong, but it requires disclosure and scrutiny that the editorial board does not provide. I know from personal experience that industry-funded research is typically rigged to support conclusions the funder wants to convey – to policymakers, the business community, the media and the public – and that any data that do not support the funder’s business objectives never make it into the final report.

In the communications business, we used to call this kind of thing a “third-party validator” — research that carries the appearance of independence while advancing the funder’s interests. I helped produce the playbook. I know how this works.

The Wall Street Journal’s newsroom has done some of the most consequential health care journalism of the past decade. Its reporters negotiated extraordinary data access. They documented, with precision, how the insurance industry has extracted billions from Medicare through practices that the Pulitzer committee described as gaming the system. They named names and they showed their work. And you can be certain that every word they wrote was carefully fact-checked and vetted by the Journal’s legal team.

The editorial board is in the same building as the Journal’s newsroom. I know because I’ve been in those rooms. I know and have worked with many of the reporters who cover the health insurance business, going back to my days in the industry. I can assure you that the Journal’s reporters are among the best in the business and, unlike the editorial writers, most certainly are not motivated by ideology.

The newspaper’s editorial board owes readers the same fidelity to evidence that its reporters have demonstrated. Instead, it has produced a piece of advocacy that reads like it was drafted in a health insurance industry communications shop — cherry-picked studies, industry talking points, and a dismissal of critics as ideologues “no matter the facts.”

I have spent the years since leaving the insurance industry trying to help people understand how spin works – how it is produced, how it travels, and how it takes hold even in institutions that should know better. The Journal editorial board’s Medicare Advantage advocacy is a case study.

This should be studied in every journalism school in America: The paper that exposed Medicare Advantage’s overbilling scheme is now urging the government to make it the default plan for every senior in America. Someone needs to explain that to the reporters who spent three years proving why that is a terrible idea.

Why drugs cost so much, 101: Medicine monopolies

We’re always asking: Why do drugs cost so freaking much? 

And it’s a complicated question. There are a bunch of reasons — to be sure. But in our reporting over the years, like our stories on insulin and tuberculosis drugs, experts cited one big reason over and over again: 

The pharmaceutical industry wages sophisticated legal battles to keep monopoly control over their best selling, most lucrative drugs — blocking generic competition, and increasing their prices along the way. 

How did it come to be this way? 

In this first episode of a new series – what we’re calling An Arm and a Leg 101 – we’re doing a crash course in the history of the drug patent system.

And the rags-to-riches story of one amazing guy is going to help us do it. 

Al Engelberg got schooled in the Art of the Hustle at a young age, collecting dimes at an illegal bingo game on the Atlantic City boardwalk. 

Later, he’d put those street smarts to use as he sat at the negotiation table in Washington D.C., hashing out the details of a law that would usher in the generic drug industry as we know it. Then made millions from the rules he helped write.

And as he admits, his legacy is mixed. 

On the one hand: The rules Al Engelberg helped write — a grand bargain between generic drugmakers and patent-holding brand pharma companies — unleashed the power of generic drugs to save Americans money. 

Nine out of ten prescriptions written today get filled with a generic.

On the other hand: In the process of making his fortune, Al Engelberg discovered loopholes, gaps, and perverse incentives in that grand bargain. 

Gaps that allowed brand and generic drugmakers to profit by keeping generics for many hit drugs off the market.  

So we now spend more than ever on medicine — and more than 20 percent of Americans report skipping their medication because they can’t afford it. 

Al Engelberg, now 86, has spent the last 30 years — and millions of his own dollars — trying to close those gaps. 

“I live in a world — a pharma world — where half the people think I’m dead, and the other half wish I was,” he tells us. 

You can read more of Al’s story — plus his prescription for fixing the crisis of high drug prices — in his book, Breaking the Medicine Monopolies: Reflections of a Generic Drug Pioneer.

And you can hear our earlier reporting on drug patents here:

John Green vs. Johnson & Johnson (part 1)

John Green vs. Johnson & Johnson (part 2)

The surprising history behind insulin’s absurd price (and some hopeful signs in the wild)

An Arm and a Leg 101 is made possible in part by support from Arnold Ventures.